Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
47 hedge funds and large institutions have $28M invested in Viracta Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 7 closing their positions.
184% more call options, than puts
Call options by funds: $88K | Put options by funds: $31K
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
43% more capital invested
Capital invested by funds: $19.6M → $28M (+$8.38M)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
7% more funds holding
Funds holding: 44 → 47 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.22M |
| 2 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$1.87M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$1.8M |
| 4 |
BlackRock
New York
|
+$699K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$497K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$881K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$219K |
| 3 |
Two Sigma Investments
New York
|
-$151K |
| 4 |
BL
Bleichroeder LP
New York
|
-$99K |
| 5 |
Millennium Management
New York
|
-$65K |
VIRX Hedge Fund Activity: Q1 2020 in Review
47 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2020, worth a combined $28M — up 43% from $19.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new VIRX positions and 7 closed out — a net gain of 4 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $2.22M. The largest seller was Sphera Funds Management, cutting an estimated $881K.
- 47 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2020, up from 44 in Q4 2019.
- Funds reported $28M of Viracta Therapeutics, Inc. Common Stock stock for Q1 2020, up 43% quarter-over-quarter.
- 11 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2020 and 7 closed out, a net change of +4 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2020 was Citadel Advisors, an estimated $2.22M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2020 was Sphera Funds Management, an estimated $881K sold.
Based on aggregated 13F filings for Q1 2020.